First Time Loading...
T

Talis Biomedical Corp
NASDAQ:TLIS

Watchlist Manager
Talis Biomedical Corp
NASDAQ:TLIS
Watchlist
Price: 9.2002 USD 2.11% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

TLIS doesn't have a meaningful market cap.
TLIS's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Talis Biomedical Corp. develops and commercialize innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. [ Read More ]

The intrinsic value of one TLIS stock under the Base Case scenario is 30.1443 USD. Compared to the current market price of 9.2002 USD, Talis Biomedical Corp is Undervalued by 69%.

Key Points:
TLIS Intrinsic Value
Base Case
30.1443 USD
Undervaluation 69%
Intrinsic Value
Price
T
Worst Case
Base Case
Best Case

Valuation Backtest
Talis Biomedical Corp

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling TLIS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Talis Biomedical Corp

Provide an overview of the primary business activities
of Talis Biomedical Corp.

What unique competitive advantages
does Talis Biomedical Corp hold over its rivals?

What risks and challenges
does Talis Biomedical Corp face in the near future?

Has there been any significant insider trading activity
in Talis Biomedical Corp recently?

Summarize the latest earnings call
of Talis Biomedical Corp.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Talis Biomedical Corp.

Provide P/S
for Talis Biomedical Corp.

Provide P/E
for Talis Biomedical Corp.

Provide P/OCF
for Talis Biomedical Corp.

Provide P/FCFE
for Talis Biomedical Corp.

Provide P/B
for Talis Biomedical Corp.

Provide EV/S
for Talis Biomedical Corp.

Provide EV/GP
for Talis Biomedical Corp.

Provide EV/EBITDA
for Talis Biomedical Corp.

Provide EV/EBIT
for Talis Biomedical Corp.

Provide EV/OCF
for Talis Biomedical Corp.

Provide EV/FCFF
for Talis Biomedical Corp.

Provide EV/IC
for Talis Biomedical Corp.

Show me price targets
for Talis Biomedical Corp made by professional analysts.

What are the Revenue projections
for Talis Biomedical Corp?

How accurate were the past Revenue estimates
for Talis Biomedical Corp?

What are the Net Income projections
for Talis Biomedical Corp?

How accurate were the past Net Income estimates
for Talis Biomedical Corp?

What are the EPS projections
for Talis Biomedical Corp?

How accurate were the past EPS estimates
for Talis Biomedical Corp?

What are the EBIT projections
for Talis Biomedical Corp?

How accurate were the past EBIT estimates
for Talis Biomedical Corp?

Compare the revenue forecasts
for Talis Biomedical Corp with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Talis Biomedical Corp and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Talis Biomedical Corp against its competitors.

Analyze the profit margins
(gross, operating, and net) of Talis Biomedical Corp compared to its peers.

Compare the P/E ratios
of Talis Biomedical Corp against its peers.

Discuss the investment returns and shareholder value creation
comparing Talis Biomedical Corp with its peers.

Analyze the financial leverage
of Talis Biomedical Corp compared to its main competitors.

Show all profitability ratios
for Talis Biomedical Corp.

Provide ROE
for Talis Biomedical Corp.

Provide ROA
for Talis Biomedical Corp.

Provide ROIC
for Talis Biomedical Corp.

Provide ROCE
for Talis Biomedical Corp.

Provide Gross Margin
for Talis Biomedical Corp.

Provide Operating Margin
for Talis Biomedical Corp.

Provide Net Margin
for Talis Biomedical Corp.

Provide FCF Margin
for Talis Biomedical Corp.

Show all solvency ratios
for Talis Biomedical Corp.

Provide D/E Ratio
for Talis Biomedical Corp.

Provide D/A Ratio
for Talis Biomedical Corp.

Provide Interest Coverage Ratio
for Talis Biomedical Corp.

Provide Altman Z-Score Ratio
for Talis Biomedical Corp.

Provide Quick Ratio
for Talis Biomedical Corp.

Provide Current Ratio
for Talis Biomedical Corp.

Provide Cash Ratio
for Talis Biomedical Corp.

What is the historical Revenue growth
over the last 5 years for Talis Biomedical Corp?

What is the historical Net Income growth
over the last 5 years for Talis Biomedical Corp?

What is the current Free Cash Flow
of Talis Biomedical Corp?

Discuss the annual earnings per share (EPS)
trend over the past five years for Talis Biomedical Corp.

Financials

Balance Sheet Decomposition
Talis Biomedical Corp

Current Assets 89.5m
Cash & Short-Term Investments 88m
Receivables 5k
Other Current Assets 1.5m
Non-Current Assets 17.7m
PP&E 16.2m
Other Non-Current Assets 1.5m
Current Liabilities 8.5m
Accounts Payable 2.7m
Accrued Liabilities 5.8m
Non-Current Liabilities 17.2m
Other Non-Current Liabilities 17.2m
Efficiency

Earnings Waterfall
Talis Biomedical Corp

Revenue
2.2m USD
Cost of Revenue
-2.4m USD
Gross Profit
-176k USD
Operating Expenses
-77.5m USD
Operating Income
-77.7m USD
Other Expenses
2.2m USD
Net Income
-75.5m USD

Free Cash Flow Analysis
Talis Biomedical Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

TLIS Profitability Score
Profitability Due Diligence

Talis Biomedical Corp's profitability score is 11/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
ROIC is Increasing
Negative 1-Year Revenue Growth
Declining ROE
11/100
Profitability
Score

Talis Biomedical Corp's profitability score is 11/100. The higher the profitability score, the more profitable the company is.

TLIS Solvency Score
Solvency Due Diligence

Talis Biomedical Corp's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Talis Biomedical Corp's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TLIS Price Targets Summary
Talis Biomedical Corp

Wall Street analysts forecast TLIS stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TLIS is 5 USD .

Lowest
Price Target
Not Available
Average
Price Target
5 USD
46% Downside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

TLIS Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

TLIS Price
Talis Biomedical Corp

1M 1M
+3%
6M 6M
+101%
1Y 1Y
+23%
3Y 3Y
-95%
5Y 5Y
+13 043%
10Y 10Y
+13 043%
Annual Price Range
9.2002
52w Low
4.36
52w High
9.25
Price Metrics
Average Annual Return 44 798.7%
Standard Deviation of Annual Returns 63 479.82%
Max Drawdown -99%
Shares Statistics
Market Capitalization 16.7m USD
Shares Outstanding 1 821 990
Percentage of Shares Shorted 1.14%

TLIS Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Talis Biomedical Corp

Country

United States of America

Industry

Health Care

Market Cap

16.7m USD

Dividend Yield

0%

Description

Talis Biomedical Corp. develops and commercialize innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company is headquartered in Menlo Park, California. The company went IPO on 2021-02-12. (Talis) Is engaged in developing molecular diagnostic tests for infectious diseases at the point of care. The firm is focused on developing and commercializing products that are designed to enable molecular testing for infectious diseases and other conditions. Talis is developing the Talis One platform, a cloud-enabled molecular diagnostic platform. The Talis One platform comprises a compact instrument, single-use test cartridges and software, including a central cloud database, which work together and are designed to provide central laboratory levels of accuracy. The platform is designed for use in non-laboratory settings, such as physicians’ offices, hospital emergency departments, urgent care clinics, ambulatory surgery centers, assisted living facilities, and cancer treatment and dialysis centers. The firm is also developing Talis One tests for respiratory infections, infections related to women’s health and sexually transmitted infections.

Contact

CALIFORNIA
Menlo Park
230 Constitution Drive
+16504333000.0
https://talisbio.com/

IPO

2021-02-12

Employees

133

Officers

CEO & Director
Mr. Robert Kelley MBA
President & Chief Scientific Officer
Dr. Andrew A. Lukowiak Ph.D.
Co-Founder & Director
Dr. Rustem F. Ismagilov Ph.D.
Interim Chief Financial Officer
Ms. Rebecca Markovich
Co-Founder and Director of Technology & Strategy
Mr. Liang Li Ph.D.
Senior Vice President of Corporate Communications & Investor Relations
Ms. Emily Faucette
Show More
Senior Vice President of Legal
Ms. Jill Green
Vice President of Human Resource
Mr. Matthew Pepe
Controller
Ms. Margaret Barrett M.S.
Company Secretary
Gillian Green
Show Less

See Also

Discover More
What is the Intrinsic Value of one TLIS stock?

The intrinsic value of one TLIS stock under the Base Case scenario is 30.1443 USD.

Is TLIS stock undervalued or overvalued?

Compared to the current market price of 9.2002 USD, Talis Biomedical Corp is Undervalued by 69%.